Skip to content
Tenfell
Awarded contract
Published 26 Feb 2024

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

NHS England · London

Key facts

Awarded
26 Jan 2024
Contract starts
01 Mar 2024
Contract ends
31 Aug 2026
Procedure
Open procedure (above threshold)
Buyer type
Central government

Awarded to 39 suppliers

SupplierValue
Almirall Ltd—
CST Pharma Ltd—
Dr Reddy's Laboratories (UK) Ltd—
GlaxoSmithKline—
Janssen-Cilag Ltd—
Orifarm UK—
Pfizer Ltd—
Teva UK Ltd—
Bayer plc—
Abbvie Ltd—
Amgen Ltd—
Aventis Pharma Ltd T/A Sanofi—
Chugai Pharma Uk Ltd—
Napp Pharmaceuticals—
Sandoz Ltd—
Thornton & Ross Ltd—
Accord-UK Ltd—
AstraZeneca—
Biogen—
Celltrion Healthcare United Kingdom Limited—
Eli Lilly & Company Ltd—
Galapagos Biotech UK Ltd—
Gedeon Richter UK Ltd—
Ipsen—
Kent Pharma Ltd—
Merck Serono Limited—
Merck Sharpe & Dohme (UK) Limited—
Mylan—
Neon Healthcare Ltd—
Novartis Pharmaceuticals UK Ltd—
Novo Nordisk—
Organon Pharmaceuticals UK Ltd—
Roche Products Ltd—
Sobi (Swedish Orphan Biovitrum Ltd)—
Sun Pharma UK Ltd—
Zentiva Pharma UK Ltd—
Pharmacosmos UK Ltd—
Vifor Pharma UK Limited—
Merz—

Description

Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

Offer reference number: CM/PHR/22/5678

CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder (Open Government Licence v3.0). Always read the original notice before responding.